UL vs. GSK
UL (The Unilever Group) and GSK (GlaxoSmithKline plc) are both stocks. UL operates in Household & Personal Products (Consumer Defensive), while GSK operates in Drug Manufacturers - General (Healthcare). Over the past 10 years, UL returned 4.43%/yr vs 4.64%/yr for GSK. At a 0.40 correlation, their price movements are largely independent.
Performance
UL vs. GSK - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, UL achieves a -12.75% return, which is significantly lower than GSK's 4.91% return. Both investments have delivered pretty close results over the past 10 years, with UL having a 4.43% annualized return and GSK not far ahead at 4.64%.
UL
- 1D
- -1.11%
- 1M
- -3.03%
- YTD
- -12.75%
- 6M
- -8.37%
- 1Y
- -18.21%
- 3Y*
- 3.46%
- 5Y*
- -0.18%
- 10Y*
- 4.43%
GSK
- 1D
- -1.71%
- 1M
- 1.25%
- YTD
- 4.91%
- 6M
- 6.15%
- 1Y
- 27.36%
- 3Y*
- 17.87%
- 5Y*
- 4.68%
- 10Y*
- 4.64%
UL vs. GSK - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
UL The Unilever Group | -12.75% | 5.96% | 20.90% | -0.17% | -2.82% | -7.61% | 9.04% | 12.88% | -2.34% | 40.15% |
GSK GlaxoSmithKline plc | 4.91% | 51.23% | -5.14% | 9.71% | -33.41% | 26.74% | -17.72% | 29.24% | 13.79% | -2.97% |
Correlation
The correlation between UL and GSK is 0.34, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.34 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.34 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.37 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.41 |
Correlation (All Time) Calculated using the full available price history since Jan 4, 1988 | 0.40 |
Fundamentals
UL:
$123.13B
GSK:
$103.15B
UL:
$5.06
GSK:
$2.85
UL:
11.08
GSK:
17.78
UL:
2.17
GSK:
1.19
UL:
1.20
GSK:
3.16
UL:
7.93
GSK:
4.38
UL:
$109.27B
GSK:
$32.78B
UL:
$90.89B
GSK:
$23.87B
UL:
$24.12B
GSK:
$11.30B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
UL vs. GSK — Risk / Return Rank
UL
GSK
UL vs. GSK - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for The Unilever Group (UL) and GlaxoSmithKline plc (GSK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| UL | GSK | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.88 | ||
| Sortino ratioReturn per unit of downside risk | -2.69 | ||
| Omega ratioGain probability vs. loss probability | 0.87 | 1.19 | -0.33 |
| Calmar ratioReturn relative to maximum drawdown | -0.73 | 1.48 | -2.20 |
| Martin ratioReturn relative to average drawdown | -1.53 | 3.38 | -4.91 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| UL | GSK | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | -0.86 | 1.02 | -1.88 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | -0.01 | 0.19 | -0.20 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.21 | 0.20 | 0.00 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.39 | 0.32 | +0.07 |
Drawdowns
UL vs. GSK - Drawdown Comparison
The maximum UL drawdown since its inception was -53.55%, roughly equal to the maximum GSK drawdown of -55.70%. Use the drawdown chart below to compare losses from any high point for UL and GSK.
Loading charts...
Drawdown Indicators
| UL | GSK | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -53.55% | -55.70% | +2.15% |
Max Drawdown (1Y)Largest decline over 1 year | -25.09% | -18.63% | -6.46% |
Max Drawdown (3Y)Largest decline over 3 years | -25.09% | -28.46% | +3.37% |
Max Drawdown (5Y)Largest decline over 5 years | -26.53% | -50.10% | +23.57% |
Max Drawdown (10Y)Largest decline over 10 years | -30.13% | -50.10% | +19.97% |
Current DrawdownCurrent decline from peak | -23.50% | -15.91% | -7.59% |
Average DrawdownAverage peak-to-trough decline | -10.60% | -18.87% | +8.27% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 11.93% | 8.11% | +3.82% |
Volatility
UL vs. GSK - Volatility Comparison
The current volatility for The Unilever Group (UL) is 5.63%, while GlaxoSmithKline plc (GSK) has a volatility of 6.42%. This indicates that UL experiences smaller price fluctuations and is considered to be less risky than GSK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| UL | GSK | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 5.63% | 6.42% | -0.79% |
Volatility (6M)Calculated over the trailing 6-month period | 18.17% | 18.51% | -0.34% |
Volatility (1Y)Calculated over the trailing 1-year period | 21.26% | 26.94% | -5.68% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 20.83% | 25.06% | -4.23% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 21.62% | 22.89% | -1.27% |
Dividends
UL vs. GSK - Dividend Comparison
UL's dividend yield for the trailing twelve months is around 4.07%, more than GSK's 3.41% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
GSK GlaxoSmithKline plc | 3.41% | 3.42% | 4.60% | 3.75% | 5.47% | 4.99% | 5.59% | 4.35% | 5.65% | 5.83% | 6.86% | 5.93% |
UL The Unilever Group | 4.07% | 3.51% | 3.29% | 3.83% | 3.57% | 3.77% | 3.07% | 3.18% | 3.49% | 2.80% | 3.42% | 3.02% |
Financials
UL vs. GSK - Financials Comparison
This section allows you to compare key financial metrics between The Unilever Group and GlaxoSmithKline plc. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
UL vs. GSK - Profitability Comparison
UL - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, The Unilever Group reported a gross profit of 0.00 and revenue of 18.38B. Therefore, the gross margin over that period was 0.0%.
GSK - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a gross profit of 5.75B and revenue of 7.63B. Therefore, the gross margin over that period was 75.4%.
UL - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, The Unilever Group reported an operating income of 4.13B and revenue of 18.38B, resulting in an operating margin of 22.5%.
GSK - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported an operating income of 2.29B and revenue of 7.63B, resulting in an operating margin of 30.1%.
UL - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, The Unilever Group reported a net income of 2.56B and revenue of 18.38B, resulting in a net margin of 14.0%.
GSK - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, GlaxoSmithKline plc reported a net income of 1.74B and revenue of 7.63B, resulting in a net margin of 22.8%.
Frequently Asked Questions
UL and GSK have a correlation of 0.34, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
GSK has higher volatility (6.42%) compared to UL (5.63%). In terms of maximum drawdown, UL dropped -53.55% vs GSK's -55.70%.
GSK currently has the higher Sharpe Ratio (1.02 vs -0.86), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for UL and GSK
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer